MedPath

Evaluating the efficacy and safety of (Embella®) in management of superficial lipomas

Phase 4
Not yet recruiting
Conditions
superficial lipoma.
Benign lipomatous neoplasm
Registration Number
IRCT20240416061507N2
Lead Sponsor
Espad pharmed
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
10
Inclusion Criteria

having at least one lipoma (clinically and sonographically proven) and accessible for diagnostic and therapeutic approaches with at least two vertical axes measurable and with the following conditions:The history of gradual growth, stability in the last 6 months, single and isolated, with an oval to circular shape, without a hard consistency or connection to the underlying tissue, in the areas of the limbs and trunk and away from sensitive vascular-neural structures
Weight stability and body mass index less than 30 in the last 3 months
Ability to complete the study and follow instructions
Informed consent to participate in the study
Consent not to undergo any other intervention for lipoma during the study period

Exclusion Criteria

Severe medical or psychological conditions that interfere with study results
History of hypersensitivity to any of the components of the studied product
Pregnancy and breastfeeding
History of previous lipoma treatment
BMI >??
Patients prone to intravascular volume depletion
Evidence of recent alcohol consumption or drug abuse
History of bleeding disorders or recent intake (less than 3 weeks) of thrombolytic drugs, anticoagulants, platelet inhibitors, or NSAIDs
History of hypertrophic scarring
Infection, inflammation, dermatosis, non-healing wound, cancer or precancerous lesions at the lipoma site

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ipoma size reduction percentage. Timepoint: At the beginning of the study, before each injection session monthly up to 3 times, one month after the last injection. Method of measurement: Ultrasound.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath